ABI1 and hepatocellular carcinoma: Moreover, CRISPR/Cas9-mediated ablation of the checkpoint kinase WEE1(106), V-set pre-B-cell surrogate light chain 1 (VPREB1) (Khaled et al., 2021), Abl interactor 1 (Abi1) (Faulkner et al., 2020), baculoviral inhibitor of apoptosis repeat-containing 5 (BIRC5) (Narimani et al., 2019), and histone deacetylase 1 and 2 (HDAC1/2) supports desired anti-cancer outcomes in HCC (Liang et al., 2020), multiple myeloma (MM) (Khaled et al., 2021), BCR-ABL-induced leukemia (Faulkner et al., 2020), acute myeloid leukemia (AML) (Narimani et al., 2019), and chronic myeloid leukemia (CML), respectively.